Publications by authors named "Barbara E Clark"
Article Synopsis
- Vasoactive intestinal peptide (VIP) affects biological processes through two receptors, VIPR1 and VIPR2, but its clinical use is hindered by rapid metabolism and non-selectivity, potentially causing side effects.
- Researchers created stable, selective agonists for VIPR1 and VIPR2, demonstrating effectiveness in protecting against neurodegeneration in a Parkinson's disease mouse model.
- VIPR2 agonists not only preserved neuronal health but also reduced inflammation and shifted immune responses, indicating their potential as neuroprotective therapies for Parkinson’s disease.
